Smith & Nephew (SNN) Competitors $25.32 +0.28 (+1.12%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SNN vs. ZBH, SOLV, PEN, GKOS, BLCO, INSP, PRCT, NVST, AXNX, and NARIShould you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include Zimmer Biomet (ZBH), Solventum (SOLV), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Envista (NVST), Axonics (AXNX), and Inari Medical (NARI). These companies are all part of the "medical equipment" industry. Smith & Nephew vs. Zimmer Biomet Solventum Penumbra Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Envista Axonics Inari Medical Smith & Nephew (NYSE:SNN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Which has preferable valuation and earnings, SNN or ZBH? Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew$5.55B1.99$263M$1.9712.85Zimmer Biomet$7.39B2.97$1.02B$5.2620.96 Do insiders & institutionals believe in SNN or ZBH? 25.6% of Smith & Nephew shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor SNN or ZBH? In the previous week, Zimmer Biomet had 24 more articles in the media than Smith & Nephew. MarketBeat recorded 24 mentions for Zimmer Biomet and 0 mentions for Smith & Nephew. Zimmer Biomet's average media sentiment score of 1.06 beat Smith & Nephew's score of 0.00 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Overall Sentiment Smith & Nephew Neutral Zimmer Biomet Positive Which has more volatility and risk, SNN or ZBH? Smith & Nephew has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Is SNN or ZBH more profitable? Zimmer Biomet has a net margin of 14.27% compared to Smith & Nephew's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Smith & Nephew's return on equity.Company Net Margins Return on Equity Return on Assets Smith & NephewN/A N/A N/A Zimmer Biomet 14.27%12.95%7.55% Does the MarketBeat Community believe in SNN or ZBH? Zimmer Biomet received 451 more outperform votes than Smith & Nephew when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 54.43% of users gave Smith & Nephew an outperform vote. CompanyUnderperformOutperformSmith & NephewOutperform Votes44854.43% Underperform Votes37545.57% Zimmer BiometOutperform Votes89967.24% Underperform Votes43832.76% Do analysts rate SNN or ZBH? Zimmer Biomet has a consensus price target of $123.22, suggesting a potential upside of 11.79%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Smith & Nephew.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Zimmer Biomet 2 Sell rating(s) 12 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is SNN or ZBH a better dividend stock? Smith & Nephew pays an annual dividend of $0.55 per share and has a dividend yield of 2.2%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. Smith & Nephew pays out 27.9% of its earnings in the form of a dividend. Zimmer Biomet pays out 18.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. SummaryZimmer Biomet beats Smith & Nephew on 17 of the 20 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Smith & Nephew News Delivered to You Automatically Sign up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNN vs. The Competition Export to ExcelMetricSmith & NephewSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$11.07B$10.30B$5.38B$20.14BDividend Yield2.14%1.10%5.13%3.50%P/E Ratio12.8524.12105.1444.57Price / Sales1.9930.171,233.1517.74Price / Cash7.9423.2340.4121.28Price / Book2.124.947.094.71Net Income$263M$182.72M$119.65M$986.85M7 Day Performance1.73%6.33%2.25%3.76%1 Month Performance-13.38%-0.07%-2.33%4.65%1 Year Performance-1.40%-1.91%33.98%27.72% Smith & Nephew Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNNSmith & Nephew3.2211 of 5 stars$25.32+1.1%N/A-1.4%$11.07B$5.55B12.8518,452ZBHZimmer Biomet4.7528 of 5 stars$108.40-0.8%$123.22+13.7%-3.2%$21.75B$7.60B20.6118,000Analyst RevisionPositive NewsSOLVSolventum1.6383 of 5 stars$69.63+1.8%$68.00-2.3%N/A$12.03BN/A0.0022,000PENPenumbra4.2737 of 5 stars$240.15+0.4%$227.92-5.1%+5.7%$9.22B$1.16B278.144,200Analyst ForecastInsider TradeNews CoverageGKOSGlaukos3.8616 of 5 stars$140.95-0.3%$134.55-4.5%+128.4%$7.77B$360.35M-46.90780News CoveragePositive NewsBLCOBausch + Lomb2.3317 of 5 stars$19.81+2.2%$20.91+5.5%+28.2%$6.98B$4.15B-18.8713,300INSPInspire Medical Systems4.7564 of 5 stars$186.19+0.8%$233.58+25.5%+31.0%$5.58B$624.80M172.781,011Analyst UpgradePositive NewsPRCTPROCEPT BioRobotics1.5908 of 5 stars$94.45+1.9%$89.50-5.2%+169.7%$4.93B$136.19M-48.89626Insider TradeNVSTEnvista3.6756 of 5 stars$21.39+5.0%$20.71-3.2%-10.4%$3.68B$2.57B-2.7512,800AXNXAxonics3.2771 of 5 stars$70.98flat$71.00+0.0%N/A$3.63B$366.38M-591.45610NARIInari Medical3.2798 of 5 stars$49.80+1.6%$58.89+18.3%-15.9%$2.92B$493.63M-37.071,300Insider Trade Related Companies and Tools Related Companies Zimmer Biomet Competitors Solventum Competitors Penumbra Competitors Glaukos Competitors Bausch + Lomb Competitors Inspire Medical Systems Competitors PROCEPT BioRobotics Competitors Envista Competitors Axonics Competitors Inari Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:SNN) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Smith & Nephew With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.